BL
Highly rated in
21
conditions

Dr. Bart P. Leroy

Philadelphia, PA
Highly rated in
21
conditions
Specialties:Ophthalmology
Experience:31 Years
Clinical Trials:Currently Recruiting for 1 Trial
Accepts:New Patients
Highly rated in
21
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Bart P. Leroy's experience treating your condition:
About Dr. Bart P. Leroy

Bart Leroy is an Ophthalmologist in Philadelphia, Pennsylvania. Leroy has been practicing medicine for over 31 years and is highly rated in 21 conditions, according to our data. His top areas of expertise are Leber Congenital Amaurosis, Late-Onset Retinal Degeneration, Retinitis Pigmentosa, Retinopathy Pigmentary Mental Retardation, and Cataract Removal. He is licensed to treat patients in Pennsylvania. Leroy is currently accepting new patients.

His clinical research consists of co-authoring 154 peer reviewed articles and participating in 6 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Bart P. Leroy it is best to call his office and ask if your insurance is accepted.

Dr. Bart P. Leroy accepts the following insurance:

  •  Ambetter
Locations
34th & Civic Center Blvd, Children's Hospital Of Philadelphia, Philadelphia, PA 19104
Background & Education
Graduate Institution
Other, 1992
Specialties
Ophthalmology
Licenses
Ophthalmology in PA
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials
An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects <8 Years of Age With Leber Congenital Amaurosis Type 10 (LCA10) Due to the c.2991 +1655A>G (p.Cys998X) Mutation.
Enrollment Status: Recruiting
Publish Date: March 25, 2022
Intervention Type: Drug
Study Drug: Sepofarsen
Study Phase: Phase 2/Phase 3
Evaluation of Light Sensitivity and Visual Acuity Changes as Consequence of Rigid Gas Permeable (RGP) Scleral Contact Lenses With a Passive Artificial Iris
Enrollment Status: Terminated
Publish Date: April 27, 2022
Intervention Type: Device, Drug
Study Phase: Not Applicable
Translational Stem Cell Research in Ophthalmology - Regenerating the Anterior Cornea Through Standardized Transplantation of Limbal Epithelial Stem Cells: a Phase II Multicenter Trial
Enrollment Status: Unknown status
Publish Date: August 31, 2016
Intervention Type: Biological
Study Drug: Limbal epithelial stem cell graft
Study Phase: Phase 2
Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Enrollment Status: Active, not recruiting
Publish Date: March 17, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2/Phase 3
An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Enrollment Status: Active, not recruiting
Publish Date: February 09, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year
Enrollment Status: Active, not recruiting
Publish Date: August 03, 2022
Intervention Type: Drug, Genetic
Study Phase: Phase 3
View 5 Less Clinical Trials -
154 Total Publications
Outcome of cataract surgery in patients with retinitis pigmentosa.
Journal: American journal of ophthalmology
Published: May 30, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
CS
Carol L. Shields
Dr. Carol L. Shields
Ophthalmology
Highly rated in
47
conditions
Ophthalmology

Wills Eye Hospital

840 Walnut St, 
Philadelphia, PA 
 2.1 mi

Carol Shields is an Ophthalmologist in Philadelphia, Pennsylvania. Shields has been practicing medicine for over 40 years and is highly rated in 47 conditions, according to our data. Her top areas of expertise are Melanoma of the Eye, Retinoblastoma, Coats Disease, Cataract Removal, and Tissue Biopsy. She is licensed to treat patients in Pennsylvania. Shields is currently accepting new patients.

TA
Dr. Tomas S. Aleman
Ophthalmology
Highly rated in
20
conditions
Ophthalmology

Penn Medicine

Penn Presbyterian Medical Center

51 N 39th St, 
Philadelphia, PA 
 0.8 mi

Tomas Aleman is an Ophthalmologist in Philadelphia, Pennsylvania. Aleman has been practicing medicine for over 35 years and is highly rated in 20 conditions, according to our data. His top areas of expertise are Choroideremia, Leber Congenital Amaurosis, Cone Dystrophy, and Retinitis Pigmentosa. He is licensed to treat patients in Pennsylvania. Aleman is currently accepting new patients.

AH
Dr. Allen C. Ho
Ophthalmology
Highly rated in
18
conditions
Ophthalmology

Main Line Health

Wills Eye Hospital

840 Walnut St, 
Philadelphia, PA 
 2.1 mi

Allen Ho is an Ophthalmologist in Philadelphia, Pennsylvania. Ho has been practicing medicine for over 35 years and is highly rated in 18 conditions, according to our data. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Retinal Vein Occlusion, Cataract Removal, and Corneal Transplant. He is licensed to treat patients in New Jersey and Pennsylvania. Ho is currently accepting new patients.